Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we deeply mined the integrated large-scale datasets from public microarrays and immunohistochemistry to validate the overexpression of BIRC5 and SQSTM1 while down-regulated FOXO1 expression in HCC.
|
29707114 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides, genes BIRC5, CDC20, CCNB1, BUB1B, MAD2L1 and CDK1 as the hub genes might play important roles for diagnosing and therapy of HCC.
|
25753876 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, plasmid-based siRNA against Birc5 and/or Hspa5 were constructed and transfected into the human hepatocellular liver carcinoma cell line, HepG2.
|
22581315 |
2012 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared the same and different activated and inhibited BIRC5 network with GO analysis between no-tumor hepatitis/cirrhosis and HCC, our result showed BIRC5 cell cycle network weaker transcription factor activity in both no-tumor hepatitis/cirrhosis and HCC (1); stronger nucleus protein binding but weaker cytoplasm protein binding in no-tumor hepatitis/cirrhosis (2); stronger cytoplasm protein phosphatase binding but weaker ubiquitin-protein ligase activity in HCC (3).
|
21312234 |
2011 |
Liver carcinoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
|
20514400 |
2010 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
|
20514400 |
2010 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
[Clinical significance of the relationship between expression of survivin and effects of neoadjuvant chemotherapy in locally advanced breast cancer].
|
18701842 |
2008 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
|
18451232 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells.
|
18242580 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, BIRC5 expression may induce breast tumor proliferation by promoting genetic instability.
|
18181175 |
2008 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis.
|
18593928 |
2008 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
[Down-regulation of survivin in growth inhibition of hepatoma cells induced by a selective cyclooxygenase-2 inhibitor].
|
18815458 |
2008 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Changes of survivin mRNA and protein expression during paclitaxel treatment in breast cancer cells.
|
17393113 |
2007 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma.
|
18069771 |
2007 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition.
|
17879398 |
2007 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
|
17170079 |
2006 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.
|
16818634 |
2006 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
|
16873289 |
2006 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
|
17087938 |
2006 |
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.
|
15569667 |
2005 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.
|
15611790 |
2005 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Detection of autoantibodies to survivin and livin in sera from patients with breast cancer.
|
16026775 |
2005 |
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Distinct expression of Survivin splice variants in breast carcinomas.
|
16142334 |
2005 |
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
|
16322251 |
2005 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.
|
16211302 |
2005 |